Unbuzzd Wellness to Host Investor Webinar on Alcohol Metabolism Beverage Opportunity
TL;DR
Quantum BioPharma's licensee Unbuzzd Wellness offers investors a Reg D 506(c) opportunity to gain early access to a scientifically proven alcohol metabolism beverage.
Unbuzzd Wellness will host an investor webinar on September 16, 2025, featuring clinical data review and sales acceleration strategies for their alcohol metabolism beverage.
Unbuzzd's beverage technology accelerates alcohol metabolism and reduces hangover symptoms, potentially improving public health and safety related to alcohol consumption.
Quantum BioPharma's spin-off Unbuzzd Wellness developed a beverage that scientifically accelerates alcohol metabolism and restores mental clarity.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced that its licensee Unbuzzd Wellness will host an Investor Webinar on September 16, 2025, at 1:30 p.m. PT / 4:30 p.m. ET. The event will feature CEO John Duffy, Advisor Jason Sawyer, Medical Director Dr. Eric Hoskins, and Board Co-Chair Gerry David presenting the current Reg D 506(c) investment opportunity.
The webinar will review clinical data and highlight strategies to accelerate direct-to-consumer, distributor, and retail sales of unbuzzd(TM), the scientifically proven beverage designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms. This presentation comes at a critical time as consumer demand for alcohol-related wellness products continues to grow globally.
Quantum BioPharma retains significant financial interest in Unbuzzd Wellness, owning 20.11% of the company as of March 31, 2025, and receiving royalty payments of 7% of sales from unbuzzd(TM) until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company maintains 100% rights to develop similar products for pharmaceutical and medical uses, positioning itself across both consumer and medical markets.
Investors can access additional company information through Quantum BioPharma's newsroom at https://ibn.fm/QNTM. The webinar represents an important opportunity for potential investors to evaluate the commercial potential of alcohol metabolism technology and understand the scientific validation behind the product claims.
The timing of this investor presentation coincides with increasing market interest in biotech solutions addressing alcohol-related disorders and wellness products. With alcohol misuse representing a significant global health concern, products that can mitigate negative effects while maintaining scientific credibility have substantial market potential across consumer, medical, and pharmaceutical sectors.
Curated from InvestorBrandNetwork (IBN)
